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Summary The differential diagnosis of mesothelioma, primary adenocarcinomas and pleural metastases frequently causes problems. We
have used the comparative genomic hybridization (CGH) technique on 34 malignant mesotheliomas and 30 primary lung carcinomas
(adenocarcinoma, including bronchoalveolar carcinoma and large-cell anaplastic carcinoma) to compare their copy number changes and to
evaluate the use of CGH to distinguish between these two types of tumour. In mesothelioma, gains of genetic material occurred as frequently
as losses, whereas gains predominated over losses in carcinoma. In mesothelioma, the mostfrequentchanges were losses in 4q, 6q and 14q
and gains in 15q and 7p, whereas gains in 8q, 1q, 7p, 5p and 6p were the most common changes in carcinoma. Amplification of KRAS2was
detected in two adenocarcinomas by Southern blot analysis. CGH showed gains in 12p in the same tumours. Statistically significant
differences between the two types of tumour were detected in chromosomes X, 1, 2p, 4, 8q, 1Oq, 12p, 14q, 15q and 18q. When comparing the
frequency of gains and losses between mesothelioma and lung carcinoma using discriminant analysis, the sensitivity of CGH to differentiate
mesotheliomas from lung carcinomas was 81% and the specificity 77%. The differences in DNA copy numberchanges between the two types
of tumour suggest that they are genetically different tumour entities. Although CGH cannot be used as a definitive discriminatory method, we
were able to distinguish between mesothelioma and lung carcinoma in a large proportion of the abnormal cases.
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Malignant mesothelioma is a tumour derived from mesothelial cells
lining the pleural and peritoneal spaces. About 80% of patients
suffering from mesothelioma have ahistory ofoccupational asbestos
exposure, which is considered a risk factor for its development
(Wagner et al, 1960; Chahinian et al, 1982). Genetic susceptibility,
such as inherited glutathione S-transferase Ml and N-acetyltrans-
ferase-2 gene defects, has also been suggested as a contributing
factor in asbestos-related mesothelioma (Hirvonen etal, 1996).
The differentiation of malignant mesotheliomas from primary
adenocarcinomas and pleural metastases can be difficult (Pisani et
al, 1988; Brown etal, 1993; Weiss and Battifora, 1993). The differ-
ential diagnosis is currently based on various morphological
analyses, including a combination of histological and immuno-
histochemical stains as well as electron microscopy (Brown et al,
1993; Weiss and Battifora, 1993). Generally, a panel of several
diagnostic markers is used, the most common being carcinoembry-
onic antigen (CEA), epithelial antigen (Ber-EP4) and Leu-M1
(Brown et al, 1993; Skov et al, 1994). These markers recognize
molecules expressed by epithelial but not by mesothelial cells, and
therefore the diagnosis of mesothelioma is based on negative
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immunohistochemical results. An antibody that reacts with
mesothelioma but not with lung carcinoma has been described
(Edwards and Oates, 1995). However, this antibody does not stain
formalin-fixed tissues. Recently, two antibodies (HBME-1 and
calretinin) reacting with formalin-fixed mesothelioma cells have
been reported (Miettinen and Kovatich, 1995; Doglioni etal, 1996).
Several cytogenetic studies have been performed on both
mesothelioma and non-small-cell lung carcinoma (NSCLC), but no
chromosomal aberration specific to either of the tumours has been
found. Both show very complex karyotypes with multiple numer-
ical and structural changes (Tiainen et al, 1989; Hagemeijer et al,
1990; Lukeis et al, 1990; Taguchi et al, 1993; Testa et al, 1994).
Comparative genomic hybridization (CGH) is a powerful
methdd for revealing DNA copy number changes, such as losses,
gains and amplifications of DNA sequences, in the whole tumour
genome in a single hybridization experiment. The method is based
on in situ hybridization ofdifferentially labelled tumour DNA and
normal reference DNA together with unlabelled Cot-I DNA
(blocks binding labelled repetitive sequences in both genomes) on
normal metaphase preparations. DNA copy number changes are
revealed by measuring the tumour-normal fluorescence intensity
ratio for each locus in the target metaphase chromosomes
(Kallioniemi et al, 1992). The advantage of CGH compared with
conventional cytogenetic analysis is that only DNA from the
specimen is required; therefore, no culturing of the tumour is
needed. Using this method, problems with low mitotic indices and
difficulties in obtaining well-banded metaphases are avoided.
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Furthermore, the genetic composition of marker chromosomes,
homogeneously staining regions and double minutes (dmin) is
resolved by CGH. However, the drawbacks are that neither
balanced translocations, inversions, small deletions nor poly-
ploidization can be detected.
In this study, we compare the copy number changes between
mesothelioma and different types of adenocarcinoma and large-
cell anaplastic carcinoma (referred to as lung carcinoma in the
text). We also evaluate the possibility of using CGH as a tool for
distinguishing these two types of tumour. Squamous cell carci-
noma of the lung does not usually present a problem for differen-
tial diagnosis and was not included. Further analysis using the
Southern blot technique was performed using a probe for the
KRAS2 gene to investigate the tumours that showed gains of
genetic material in chromosome 12p using CGH.
MATERIALS AND METHODS
Mesothelioma
Thirty-four malignant mesotheliomas from patients treated at the
Helsinki University Central Hospital were included in the study.
Only tumours with a confirmed diagnosis and specimens with
sufficient material for successful DNA extraction and CGH
analysis were selected for the study. The diagnosis was confirmed
by the Finnish National Mesothelioma Panel or by the European
Organization for Research and Treatment ofCancer Mesothelioma
Panel. There were five fibromatous, 19 epithelial and ten mixed
mesotheliomas. Thirty-three ofthe mesotheliomas were ofpleural
and one ofperitoneal origin. Twenty-four patients had a history of
asbestos exposure, nine patients were not aware ofany exposure to
asbestos, and the asbestos exposure in one patient was not known.
Thirty of the specimens were formalin fixed and paraffin
embedded; four were fresh frozen tumours (case nos 20, 21, 23
and 24) (Table 1).
Lung carcinoma
Ten adenocarcinomas, ten bronchoalveolar and ten large-cell
anaplastic carcinomas were selected from the files of the
Department of Pathology, University of Helsinki (Table 1). The
specimens were formalin fixed and paraffin embedded. We
selected the ten most recently diagnosed carcinomas in each group
with sufficient material for the analyses.
DNA extraction
Sections were examined and the tumour area was marked. All
irrelevant material was cut away and a new paraffin block was
made of the remaining tumour tissue that contained at least 60%
malignant cells. Thirty 3- to 5 gm-thick sections were cut and
DNA extraction was performed as described elsewhere (Miller et
al, 1988; Isola et al, 1994). DNA in peripheral blood specimens
from healthy donors (male and female) was extracted according to
standard procedures and used as reference in the CGH analyses.
CGH analysis
The CGH analyses were performed according to the method of
Kallioniemi et al (1994), with some minor modifications. In brief,
800 ng of fluorescein isothiocyanate (FlTC)-dUTP (Du Pont NEN
Products, Boston, MA, USA)-labelled tumour DNA and 800 ng of
Texas Red-dUTP (Du Pont)-labelled normal reference DNA
together with 20 jig ofunlabelled human Cot-I DNA (Gibco BRL,
Gaithersburg, MD, USA) in 10 jl of hybridization buffer [50%
formamide, 10% dextran sulphate, 2xSSC (lxSSC is 0.15 M
sodium chloride/0.015 M sodium citrate, pH 7)] were denatured at
75°C for 5 min and applied to normal lymphocyte metaphase
preparations. Before hybridization, the preparations were stored in
a fixative solution (methanol-acetic acid, 3:1) for one night,
pretreated in 2xSSC at 40°C for 30 min and dehydrated in a series
of 70%, 85% and 100% ethanol. The preparations were denatured
at 65-670C for 2 min in a formamide solution (70% form-
amide/2xSSC) followed by dehydration on ice as described above
and treatment with proteinase K. Hybridization (2-3 days at 37°C)
was followed by washes to remove unspecifically bound DNA,
after which the preparations were counterstained with 4, 6-
diamidino-2-phenyl-indole-dihydrochloride (DAPI; Sigma, St
Louis, MO, USA) and covered with an antifade solution (Vector
Laboratories, Burlingame, CA, USA). To confirm the CGH results,
additional hybridization experiments using the reverse-labelling
system, i.e. tumour DNA labelled with Texas Red and reference
DNA with FITC, were performed on some specimens.
Digital image analysis, interpretation and quality
control of the CGH results
An Olympus fluorescence microscope and the isis digital image
analysis system (MetaSystems, Altlussheim, Germany) based on a
high-sensitivity integrated monochrome CCD camera and an auto-
mated CGH analysis software package were used to analyse the
hybridization (fordetails, see Kivipensas et al, 1996). A region in a
chromosome was considered as being over-represented (gained)
when the ratio exceeded 1.17 and under-represented (lost) when
the ratio was less than 0.85. These cut-off values were based on
negative control hybridization experiments, i.e. hybridization of
two normal DNAs. Only ratio changes that exceeded the fluctua-
tion seen in the negative control experiments were interpreted as
evidence of a real gain or loss of DNA sequences. Furthermore,
positive control experiments with tumour DNA of known DNA
copy number changes (both losses and gains) were performed to
confirm the cut-offvalues mentioned above. In orderto distinguish
--between different levels ofgain/ratios exceeding the values of 1.3
or 1.5 were considered as amplifications or high-level amplifica-
tions respectively. Furthermore, intra-experiment standard devia-
tions for every position in the CGH ratio profiles were calculated
from the variation of the ratio values of all homologous chromo-
somes within the experiment. Confidence intervals for the ratio
profiles were then calculated by combining them with an empirical
inter-experiment standard deviation and estimating error proba-
bility of 1% based on the t-distribution. The heterochromatic
regions in chromosomes 1, 9 and 16, the p-arms ofthe acrocentric
chromosomes and the Y chromosome were excluded from the
analyses because ofsuppression ofhybridization with Cot-I DNA
in these regions. Gains (.1.17 and <1.3) of genetic material in
chromosomes lp32-pter, 16p, 19 and 22 were not included
because ofthe false-positive results revealed in these chromosomal
areas in the negative control experiments.
Southern blot analysis
The Southern blot method was used to investigate possible amplifi-
cation ofthe KRAS2 gene (probe p640, providedby R Weinberg) in
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Table 1 CGH findings from 34 patients with malignant mesothelioma and 30 patients with primary adeno- or large-cell anaplastic carcinoma
Case Losses Gains Amplifications High-level
(sex/age at (<0.85) (> 1.17 and < 1.3) (.1.3 and < 1.5) amplifications
diagnosis/ (> 1.5)
exposure to
asbestos)
Mesothelioma
Fibromatous
1 (Mt77/?) 4q31.3-qter
2 (M/631-) 4qcen-q26
3 (MW56/-)
4 (M/41/+) 6qcen-q22
5 (Ff73/-)
lq, 6q21-p22, 7, 8
5q23-qter, 14q24-qter
5p
6p, 15q15-q21
8p
Epithelial
6 (F/69/-)
7 (M/55/+)
8 (M/47/+)
9 (M/551+)
10 (M1781+)
1 1 (M/631+)
12 (MW44/+)
13 (M/61/-)
14 (M/79/+)
15 (MW57/+)
16 (M/40/+)
17 (MW59/+)
18 (F/621-)
19 (MW534+)
20 (MW661+)
21 (MW44/+)
6q22-qter, 8p, 10qcen-q23, 17q21-pter
None
None
4, 5q, 9q, 14q, 22q
None
5q13-q22, 7q31-qter, 13q21-qter, 14q13-qter
1pcen-p22, 3p24-pter, 6qcen-q22, 9p, 13qcen-q22,
14q13-q21
None
None
3qcen-q25, 6, 9p21-pter, 13q13-qter
4, 9pter-q22, 10q, 13q, 14q21-qter, 15qcen-q15
6q
6qcen-q21
2q33-qter, E6q22-qter, 12p12-pter
22 (M/531+) 1p21-p31, 2q34-qter, 9p, 14q
23 (MW68/+) 4, 14q, 17p, 18p
24 (MW42+) 1pcen-p22, 22q
6q21-pter, 15q, 17q21-qter
None
None
5p, 9p
None
7p
1q, 2qcen-q14.1, 5q31-qter, 6p, 7q,
8p12-qter, 9q, 11, 12q22-qter
None
7
None
2, 7p, 15q21-qter, 21q
7q, 11
6p, 9q31-qter, 15q
2q24-qter, 11q14-q22
5,7,8
lqcen-q41, 15qcen-q14, 15q22-qter,
17q21-qter
1q23-q41, 9q, 1 1p, 15q23-qter
3pcen-p14, 3q, 5p, 7p, 8, 13q21-qter
lq
3p22-pter, 3p14-qter, 5
None
None
None
15q22-qter
None
None
8, 10p
1qcen-q23, 1q41-qter
1 1q14-q22
15q21-qter
10, 16, 17p, 22q
1p21-p31, 4, 6q15-qter, 10, 13q, 14q13-q23
4q24-pter, 9pcen-p22, 11p14-pter, 14q
Xp, 1p, 3q23-pter, 4q, 5, 6q22-qter, 16q
4q33-qter, 16p
None
4p15.3-qter, 6q16-qter, 9p, 1Oq23-pter
14q, 16q
None
13q
Lung carcinoma
Adenocarcinoma
35 (F/76)
36 (F/79) 17p
37 (M/80) 8p, 13q
38 (M/63)
39 (M/70)
40 (M/48)
41 (F/67)
42 (M/68)
43 (M/52)
44 (F/46)
None
8p
None
3p, 9p21-pter
4q24-qter
Bronchoalveolar
45 (M/68) 4
46 (M/73) 6q, 8p, 18
47 (M/63) 6qcen-q23
1q, 5, 6p, 7p, 8q21.1-q21.2,
8q23-qter, 14q, 17q24-qter
Xq23-qter, 1, 2q22-q24, 3, 5q23-q33,
6q21-qter, 7q, 14q
X, 1, 5q, 10p, 14q22-qter
lq, 6p, 18q
None
1, 2p15-q22, 7p, 8q21.3-qter
1Oqcen-q22, 1lqcen-q13
8q, 1Oq
None
Xp2l-qter, 1qcen-q32, 5p, 6q23-qter, 12q
lq, 2p23-pter, 6p
1qcen-q41
5, 6p, 8q
lq, 6p
X, 2p13-p16, 8q21.3-q23
5p, 5qcen-q23, 7p,
8q22-qter
14qcen-q21, 8q21.1,
8q24.1-qter
None
2q22-q32, 5p,
8qcen-q21 .2, 11q14-qter,
12pcen-p12
None
8q23--qter, 12pcen-p13
8pcen-p21
lq
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15q21-qter
7
None
None
None
None
None
1lqcen-q14,
11q22-qter
Mixed
25 (M/631+)
26 (M/57/+)
27 (M/60/-)
28 (M/55/+)
29 (Ff68/-)
30 (M/59/+)
31 (M/41/+)
32 (M/564+)
33 (M/70/-)
34 (M/57/+)
3q13.2-q26.3
9p
5p
4p
lip
None
3p21-pter
None
12p13
None
12q22-qter
12pcen-p12
None
None None
12q14-q21, 21q
5p, 7p,
8q21.1-q24.1
None
None
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Case Losses Gains Amplifications High-level
(sex/age at (< 0.85) (21.17 and < 1.3) (21.3 and < 1.5) amplifications
diagnosis/ (2 1.5)
exposure to
asbestoss)
48 (F/60) 7p21-q36, 8q
49 (M/50) 1p, 17p, 18 1q, 2p24-q34, 1Op, 13q 1Oq
50 (F/52) 8p, 12p12-pter, 18q 8q
51 (M/80) None None None None
52 (M/65) 6q, 11q23-qter 2, 6p, 7, 8qcen-q21.1, 10, 1q, 8q23-qter 12poen-p13
1 1peen-p15
53 (F/56) None None None None
54 (F/80) lqcen-q41, 7p
Large-cell anaplastic carcinoma
55 (M/60) 1Op13-pter 5p14-pter, 7qcen-q31, 11q, 1q22-q31, 7q31-qter, 8p12-q12,
12q14-qter 8q13-q23, 10q24-qter, 18 8q24.1-qter
56 (M/65) 3qcen-q24, 3q27-qter, 5pcen-p15.1, 3q25-q26
14qcen-q13, 14q24-qter, 15q22-qter
57 (M/49) 8q21.3-qter 7q22-q31
58 (F/59) X 6pcen-p21.3, 7q11.2-pter, 1Op, 12p 3q21-q26.1, 8q
59 (M/54) 17p X, 2pcen-p15, 5q, 8q, 11qcen-q14, 1q, 5p, 11pcen-p14
12q13-qter, 13q, 18qcen-q21
60 (M/60) 9p21-pter 1q, 6p, 8q22-qter 1p31-p36.1, 12pcen-p13
61 (M/57) 7
62 (Ff72) X, 6qcen-q23 2q32--qter, 12 18
63 (M/65) 13q21-q32 8qcen-q22 7q 11.2-pter, 8q23-qter
64 (F/45) X 2pter-q14.2, 10, 11qcen-q21, 12 4p, 7p, 8p12-qter
aMesothelioma patients. ?, Asbestos exposure not known; +, asbestos exposure; -, no asbestos exposure.
Table 2 Discriminant analysis of histological diagnosis and CGH findings. Method of prediction: (A) linear discriminant analysis; (B) quadratic discriminant
analysis
A
Histological Lung carcinoma Mesothelioma
diagnosis
Adenocarcinoma Bronchoalveolar Larg-cell Epithelial Fibromatous Mixed
anaplastic
Adenocarcinoma 4 - 3 - 1 -
Bronchoalveolar - 2 2 3 - 1
Large-cell anaplastic 3 - 5 2 - -
Epithelial - - 2 11 - 1
Fibromatous - 1 2 2 - -
Mixed 1 - 1 - 6
B
Histological
diagnosis Lung carcinoma Mesothelioma
Lung carcinoma 17 9
Mesothelioma 3 24
the tumours that had gains, amplifications or high-level amplifica-
tions in the short arm of chromosome 12 in the CGH analyses.
DNA was available in seven ofthe eight tumours with gain in 12p
(case nos 30, 40, 43, 52, 58, 60 and 62). Case no. 38, for which
CGH revealed a normal chromosome 12p, and a normal blood
sample were used as negative controls. The p105-153A probe
hybridizing to chromosome 5q11.2-13.3 was chosen as a control
probe because ofnormal CGH results in this region in the tumours
tested for KRAS2 amplification. HindIll-digested DNA samples
were hybridized with p640 and rehybridized with reference probe
p105-153A. Probes p640 and p105-153A hybridize to fragments
of approximately 1 kb and 3 kb respectively. The analysis and
interpretation ofthe results wereperformed as described elsewhere
(Peltomaki etal, 1991; Monni et al, 1996).
Multivariate analysis
The calculated frequencies ofDNA copy number changes and the
statistical analyses were based on those tumours that had either
gains or losses ofgenetic material.
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Table 3 Descriptive statistics of the frequency of chromosomal gains and losses in malignant mesothelioma and adeno- or
large-cell anaplastic carcinoma
Type Mean Standard Minimum Maximum
deviation
Gains
Lung carcinoma 6.0 4.1 1 13
Adenocarcinoma 7.8 4.5 2 13
Bronchoalveolar 4.0 3.3 1 11
Large-cell anaplastic 6.3 4.1 2 13
Mesothelioma 3.2 2.9 - 12
Mixed 1.0 0.8 - 2
Epithelial 4.6 3.2 1 12
Fibromatous 3.0 2.3 1 7
Losses
Lung carcinoma 1.3 1.2 - 4
Adenocarcinoma 0.9 0.8 - 2
Bronchoalveolar 2.0 1.6 - 4
Large-cell anaplastic 1.1 1.0 - 3
Mesothelioma 3.4 2.9 - 9
Mixed 4.9 3.5 - 9
Epithelial 3.5 2.3 - 7
Fibromatous 0.6 5.5 - 1
Table 4 Statistically significant differences between mesothelioma and lung carcinoma
DNA copy number Mesothelioma Lung carcinoma RR 95% Cl
changes (%) (%)
Gains
Xp 15 0 0-0.88
Xq 19 0 0-0.69
1p - 15 0 0-0.87
lq 19 62 0.30 0.13-0.66
2p 4 26 0.14 0.023-0.78
8q 19 65 0.28 0.12-0.61
1Oq - 23 0 0-0.57
12p 4 27 0.14 0.020-0.78
15q 30 4 7.7 1.4-46.7
18q - 15 0 0-0.88
Losses
4p 22 4 5.8 1.0-35.9
4q 37 8 4.8 1.3-18.7
10q 19 _ a 1.34-a
14q 33 a 2.5_a
aCategory not applicable. RR, risk ratio; Cl, confidence interval.
Discriminant analysis was used to distinguish between diag-
nostic groups based on observed DNA copy number changes. We
began by using a linear discriminant function (Fisher, 1936) as the
statistical criterion for classification of the tumours into six sepa-
rate diagnostic groups. The first discriminant function (or canon-
ical variate) was taken as the linear combination of the frequency
of the total number of losses of DNA sequences and the total
number of gains separately in the p-arm and in the q-arm; the
components were coded as four predictor variates (Gp, Gq, Lp,
Lq). These discrete variates were subjected to the Freeman-Tukey
transformation (i.e. 4G_p + 4p + 1) to approximate the normal
distribution (see Johnson and Kotz, 1969, p. 99). The linear
discriminant function has a maximal ratio of the separation ofthe'
group means to the within-group variance. The second discrimi-
nant function is the linearcombination that is uncorrelated (but not
necessarily orthogonal) to the first, which has the same optimality
criterion. The third discriminantfunction is definedanalogously. A
tumour was classified by calculating its Euclidean distance from
the diagnostic group centroids, projected onto a subspace defined
by a subset ofthe canonical variates. The tumour was assigned to
the closest group. The program output contained a discriminant
function score for each tumour and group mean values. We also
applied quadratic discrimination to these data. The altemative
allocation rule uses the smallest expected number of errors as the
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Figure 1 Gains and losses of DNA sequences in 27 mesotheliomas and 26 lung carcinomas. Losses are shown on the left side of the chromosome and gains
on the right. The first chromosome in a pair represents mesothelioma (MM), the second one represents lung carcinoma (LC). Dotted lines are amplifications
(gains 2 1.3 and < 1.5); bold lines are high-level amplifications (gains 2 1.5). Only chromosomes with changes are shown
selection criterion for allocating a tumour to the a priori specified
diagnostic group to which it has the maximum a posteriori proba-
bility of belonging. This Bayes rule can be linked to the
Mahalanobis distance (Mahalanobis, 1936) by assuming that the
groups arejointly distributed multivariate normal within the same
covariance matrix. To calculate the above discriminant analysis
functions, we used the discr, ida and qda programs implemented
in the S-PLUS system (Venables and Ripley, 1994).
Univariate analysis
The preceding multivariate analysis was supplemented with
univariate analyses of changes in a specific chromosome. This
strategy was adopted because the multivariate method discrimi-
nated between groups based on histological diagnosis, and of
interest was a comparison of different combinations of subgroups
formed on the basis of morphological characteristics. A compar-
ison of the relative frequency of the occurrence of DNA copy
number changes in a single chromosome between malignant
mesothelioma and lung carcinomas was carried out in terms ofthe
risk ratio (RR) parameter using the method of Miettinen and
Nurminen (1985).
RESULTS
Comparison of the CGH results for mesothelioma and
lung carcinoma
Multivariate analysis
Table 2A gives the cross-classification of the 53 informative
tumours into six separate subgroups based, on one hand, on the
histological diagnosis and, on the other hand, on the predicted
diagnosis by the linear discriminant function analysis of chromo-
somal changes (gains and losses in the p- and q-arm). The overall
misclassification rate was 47%. When focusing on the meso-
thelioma-lung carcinoma discrimination, 3 (case nos 1, 20 and 23)
of 27 mesotheliomas and 9 (case nos 44-47, 50, 54, 61-63) of 26
lung carcinomas were incorrectly classified by the quadratic
discriminant analysis (Table 2B). Thus the sensitivity of CGH to
differentiate a mesothelioma from a lung carcinoma was 89% and
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Figure 2 Selected CGH profiles of the most frequent gains and losses of
DNA sequences in mesothelioma and lung carcinoma. The chromosome
numbers are shown under the profiles and the case numbers on top. The line
in the middle is the base line ratio (1.0); the left and the right lines indicate
ratio values of 0.85 and 1.17
the specificity 63%. When the gains and losses in both arms were
combined, the overall error rate was 21% with 81% sensitivity and
77% specificity.
Univariate analysis
Table 3 gives the mean value and standard deviation ofthe number
ofgains and losses ofDNA sequences detected in the two different
main types of tumour and in the separate histological subgroups.
Although differences in the frequency of gains and losses were
detected between mesothelioma and lung carcinoma, they were
not statistically significant (Fisher's exact test). However, when
focusing on separate chromosomes, significant differences were
seen in X, 1, 2p, 4, 8q, 10q, 12p, 14q, 15q and 18q (Table 4).
There was no statistically significant difference between the
DNA copy number changes detected in separate chromosomes in
the threehistological subgroups ofmesothelioma. Whencombining
tumours from the fibromatous and mixed group, which is pennis-
sible because of clinical and prognostic similarities, a gain of
genetic material in 15q was found to be more common in epithelial
tumours (n = 14) than in the fibromatous mixed group (n = 13) [risk
ratio (RR) 6.5, 95% confidence interval (CI) 1.3-39.3].
Statistically significant differences in losses andgains ofgenetic
material were not detected between the three types of lung carci-
noma. When considering adenocarcinoma and bronchoalveolar
tumours as one group (n = 16), again in lq occurred more often in
them than in the tumours in the large-cell anaplastic carcinoma
group (n = 10) (RR 2.7, 95% CI 1.2-7.8).
Mesothelioma
Twenty-seven out of the 34 mesotheliomas showed DNA copy
number changes. Gains ofgenetic material occurred as frequently
as losses (Table 3). High-level amplifications wereonly detectedin
1lq and 12p (Table 1 and Figure 1).
1 2
p105-153A 9-
KRAS2
3 4
j -3kb
-1 kb
I
12
Figure 3 Southern blot analysis of tumours with gains of genetic material in
12p. Lane 1 represents case no. 43 and lane 2 case no. 40. Lanes 3 and 4
represent negative controls: case no. 38 and a normal blood sample
respectively. CGH profiles of chromosome 12 in case nos 38, 40 and 43 are
also shown
The most common aberration in the mesotheliomas was a loss
of DNA sequences in the long arm of chromosomes 4 and 6 in 10
of the 27 (37%) informative tumours. The minimal common
region of loss extended in chromosome 4 from the 4q centromere
to band q24 and 4q33 to the q-telomere and in chromosome 6 it
was only band q22. Losses occurred frequently in the long arms of
chromosomes 13 (q21-q22) and 14 (q21) and in the short arm of
chromosome 9 (p21) in 22%, 33% and 22% of the abnormal
specimens respectively (Table 1, Figures 1 and 2).
The most recurrent gain of DNA sequences was detected in the
long arm ofchromosome 15 (q23-qter) in 9 ofthe 27 (33%) infor-
mative cases. There were three amplifications among these gains.
Otherregions commonly gained in the abnormal tumours were the
short arms of chromosomes 5 (pcen-pter, 22%), 7 (pcen-pter,
26%) and 8 (pcen-p12, 22%) and the long arm of chromosome 7
(qcen-qter, 22%). Among these gains one amplification was
detected per chromosome (Table 1, Figures 1 and 2).
Lung carcinoma
DNA copy numberchanges weredetected in 26 ofthe 30 specimens
evaluated. Gains ofgenetic material predominated over losses with
a ratio of 4.6:1 (Table 3). There were high-level amplifications in
5p, 7p, 8p, 8q, 12p, 12q and 21q (Table 1, Figures 1 and 2).
A gain in DNA sequences in the long arm of chromosome 8
(q23-qter) was the most recurrent aberration found in 17 ofthe 26
(65%) informative tumours. Seven of these were amplifications
and three were high-level amplifications. More than half (62%) of
the informative specimens had gains in the long arm of chromo-
some 1 (q22-q31). Four amplifications and 12 gains were
observed in this area. Gains were also frequent in the short arms
of chromosomes 6 (pcen-p21.3, 31%), 5 (pl4, 35%) and 7
(pcen-p21, 42%). The last two included one high-level amplifica-
tion and three amplifications (Table 1, Figures 1 and 2).
Losses of DNA sequences were most common in the long arm
of chromosome 6 (qcen-q23). These aberrations were found in 4
ofthe 26 (15%) abnormal tumours. Other chromosomal areas that
were lost in three or four tumours were the short arms ofchromo-
somes 8 (pcen-pter, 15%) and 17 (pcen-pter, 12%), the long arm
of chromosome 18 (qcen-qter; 12%) and the whole X chromo-
some (pter-qter; 12%) (Table 1, Figures 1 and 2).
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Southern blot analysis
Amplification ofKRAS2 was detected in two ofthe seven tumours
with a gain of genetic material in 12p. Both of these were regular
adenocarcinomas (case nos 40 and 43). Compared with the nega-
tive controls, these carcinomas showed increased dosages (3.7-
and 8.2-fold) of KRAS2 (Figure 3). In the other five tumours, the
analysis failed because ofthe poor quality ofthe DNA.
DISCUSSION
The main result in our study is that there is a difference between the
pattem of DNA copy number changes in mesothelioma and that in
lung carcinoma. By combining the occurrence of gains and losses
of genetic material in the individual tumours, we were able to
predict the correct type oftumour in 41 ofthe 53 informative cases.
When comparing DNA copy number changes in single chromo-
somes, significant differences were detected in ten chromosomes.
Discriminant analysis for normal populations assumes that the
joint distribution of all predictors is multivariate normal. In prac-
tice, this assumption is not always valid, and even the predictor
variates are only approximately normal. Therefore we have to rely
on the robustness of the applied procedure to depart from
normality. The detected chromosome changes were originally
coded as 63 indicator variates. The sum of binary (0, 1) variates
tends to be normally distributed, and the transformation of the
summed variates helps to approximate this distributional assump-
tion. (We note parenthetically that the reduction of the number of
variates must be performed without regard to their relationship to
the outcome variate, i.e. the type of tumour - otherwise the selec-
tion procedure will be biased.) To check the stability ofthe results,
we conducted a logistic discriminant analysis that makes fewer
assumptions about the distributions of the variates. This method
yielded results similar to those obtained by the ida and qda
methods.
Nevertheless, the size of the subgroups of classified tumours
was too small - in particular, there were only five fibromatous
mesotheliomas - to form reliable predictor models. In practice, in
order to have predictive discrimination that validates a new series
of tumours, the number of variates selected for the discriminant
function should be no more than the number of tumours in the
sample that was used in fitting the model divided by ten (Harrel et
al, 1996). The size rule applies because we used four (or two)
summary variates on a sample of 53 (i.e. 4 < 53/10 5). To
discriminate between the two diagnoses (mesothelioma and lung
carcinoma), the number of tumours in the less frequent group (26)
should be at least roughly ten times higher than the number of
predictors (10 x 4 =40 or lO x 2 = 20); here the rule does not apply
when four predictors are used.
Our primary measure of accuracy of classification was the error
(or misclassification) rate, as this is the quantity that the Bayes rule
minimizes. The most stringent test of a predictor model is an
extemal validation - the application of the estimated model to a
new patient population. Unfortunately, we did not have another
series of tumours to test the performance of the model. However,
the error rate on a randomly chosen set from the whole population
will be an unbiased estimator. For this cross-validation (Efron,
1983), we first randomly allocated 53 tumours into ten mutually
exclusive subsamples. We then left out a subsample, estimated the
discriminant function model on the remaining sample and used the
fitted model to classify the previously drawn subsample. We repli-
cated this procedure for the other nine subsamples. The cross-vali-
dated error rate was then formed by averaging one minus the
posterior probability assigned to the selected class. Anotheradvan-
tage ofthis technique is that it does not depend on the correctness
of the supplied classification based on the histological diagnosis
(Venables and Ripley, 1994). The cross-validated result for the
previously obtained error rate of 21% was 26%, indicating a fair
reliability ofthe model to discriminate between mesothelioma and
lung carcinoma.
The DNA copy numberchanges detectedin mesotheliomain this
analysis, such as losses of genetic material in lp, 4q, 6q, 9p, 13q,
14q and gains in 5p and 7p, are supported by previous
cytogenetic and CGH studies, although with some differences in
frequency of occurrence (Tiainen et al, 1989; Hagemeijer et al,
1990; Taguchi et al, 1993; Kivipensas et al, 1996; Bjorkqvist et al,
1997). These chromosomal regions probably carry important genes
for the development and progression of mesothelioma. Losses of
DNA sequences in 13q were detected in six tumours in this study.
Five of these showed a loss in 13ql4 in which the RBI tumour-
suppressor gene is located. However, a study by Van der Meeren et
al (1993) on mesothelioma cell lines suggests that inactivation of
RBI is not a critical step in the development ofmesothelioma.
The most common copy number changes in non-small-cell lung
carcinoma (NSCLC) in this study were gains in 8q, lq, 7p, 5p and
6p (in decreasing order of frequency). Cytogenetic analyses of
NSCLC have detected, on average, more losses than gains ofchro-
mosomal material (Lukeis et al, 1990; Testa et al, 1994). These
results are to some extent in contrast to ours, because we detected
over four times more gains than losses. However, gains in lq, 7
and 12q have been frequent findings by cytogenetic analysis
(Lukeis et al, 1990; Testa et al, 1994) and they were also frequent
in our study. Because marker chromosomes are common cytoge-
netic findings, it is obvious that some ofthe chromosomal material
thought to be lost resides in them. CGH is a DNA-based method
and therefore the genetic material in marker chromosomes as well
as in dmin is also analysed. Furthermore, CGH reveals only clonal
aberrations that exist in at least 50% of the cells, meaning that
clonal aberrations found only in a smallproportion ofthe cells will
not be detected (Kallioniemi et al, 1994). Some of the DNA copy
number changes seen in our study, particularly high-level amplifi-
cations, represent new findings that may have an important role in
the tumorigenesis ofNSCLC. Gains ofgenetic material in the long
arm ofchromosome 8 are not often found in cytogenetic analyses.
However, the presence of isochromosome 8q has been associated
with primary adenocarcinomas (Jin et al, 1988) and gains in 8q
have been reported to be frequent in pleural effusions from
NSCLC patients (Lukeis et al, 1993). In our CGH analysis, this
particular aberration (including three high-level amplifications)
occurred in 65% of the informative tumours. Amplification of the
MYC oncogene has been detected in some NSCLCs (Cline and
Battifora, 1987; Slebos et al, 1989). MYC resides in the minimal
common region ofoverlap (8q23-qter) in our study and therefore
it is likely to be one ofthe amplified genes.
The difference in the occurrence of losses and gains of genetic
material detected in our study may suggest that mesotheliomas and
lung carcinomas develop and progress in different ways. This
hypothesis is supported by molecular analyses that have demon-
strated that mutations in the tumour-suppressor gene P53 in 17p
and the oncogene KRAS2 in 12p are frequentin NSCLCs but notin
mesotheliomas (Metcalf et al, 1992; Ridanpiia et al, 1994). We
detected amplification of KRAS2 in two adenocarcinomas and a
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gain ofgenetic material in 12p in seven carcinomas, supporting the
role of gene amplification as an alternative pathway by which
KRAS2 is activated.
Similarities, such as gains ofgenetic material in 5p, 6p and 7p,
between mesothelioma and lung carcinoma were also found. We
detected a gain in 7p in seven mesotheliomas and 11 lung carci-
nomas (including one high-level amplification). The EGFR gene,
located in 7pl2-pl3, may be one of the altered genes and may
therefore be important in the tumorigenesis of both types of
tumour. The putative tumour-suppressor genes MTS2 andMTSJ in
9p2l are deleted or mutated in both types of tumour (Xiao et al,
1995a and b). We detected deletions in 9p in six mesotheliomas
but only in two carcinomas. Based on previous published cyto-
genetic data on mesothelioma and NSCLC, a higher frequency of
losses in 9p was to be expected (Hagemeijer et al, 1990; Lukeis et
al, 1990; Taguchi et al, 1993; Testa et al, 1994). It is likely that
deletions in 9p existed in our specimens but were not detected
because ofintratumour genetic heterogeneity.
In conclusion, we found differences in DNA copy number
changes between mesothelioma and lung carcinoma, suggesting
that they are genetically different tumour entities. Although CGH
cannot be used as a definitive discriminatory method, based on the
CGH results, we were able to distinguish between mesothelioma
and lung carcinoma in 77% ofthe abnormal cases. In addition, our
CGH results ofprimary adenocarcinoma and large-cell anaplastic
carcinoma of the lung revealed new findings of losses, gains and
amplifications of genetic material, which could be important for
their development and progression.
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